<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-ONRC-13003502</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2013-08-22</date_registration>
      <primary_sponsor>The First Affiliated Hospital of Zhejiang University</primary_sponsor>
      <public_title>A multi-center, prospective, non-randomized clinical study of bortezomib / thalidomide, cyclophosphamide and dexamethasone combined with autologous hematopoietic stem cell transplantation in patients with de novo advanced multiple myeloma</public_title>
      <acronym />
      <scientific_title>A multi-center, prospective, non-randomized clinical study of bortezomib / thalidomide, cyclophosphamide and dexamethasone combined with autologous hematopoietic stem cell transplantation in patients with de novo advanced multiple myeloma</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2013-09-01</date_enrolment>
      <type_enrolment />
      <target_size>PCD chemo group:160;PCD plus ASCT group:40;TCD chemo group:160;TCD plus ASCT group:40;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=6058</url>
      <study_type>Observational study</study_type>
      <study_design>Non randomized control</study_design>
      <phase>Other</phase>
      <hc_freetext>Multiple Myeloma</hc_freetext>
      <i_freetext>PCD chemo group:Chemotherapy;PCD plus ASCT group:Chemotherapy plus ASCT;TCD chemo group:Chemotherapy;TCD plus ASCT group:Chemotherapy plus ASCT  ;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Jingsong He</firstname>
        <middlename />
        <lastname />
        <address>Building 2, 10th Floor, 79 Qingchun Road, Hangzhou, Zhejiang, China</address>
        <city />
        <country1 />
        <zip>310003</zip>
        <telephone>+86 13600547247</telephone>
        <email>hjs2005@263.net</email>
        <affiliation>The First Affiliated Hospital of Zhejiang University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Zhen Cai</firstname>
        <middlename />
        <lastname />
        <address>Building 2, 10th Floor, 79 Qingchun Road, Hangzhou, Zhejiang, China</address>
        <city />
        <country1 />
        <zip>310003</zip>
        <telephone>+86 13857190311</telephone>
        <email>caizhen1@yahoo.com</email>
        <affiliation />
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. aged 18 years to 70 years;
2. In accordance with IMWG2003/WHO 2008 (V4) MM diagnostic criteria and with measurable indicators;
3. The eastern cooperative oncology group fitness score (ECOG) &lt;=2 points, expected survival of more than three months;
4. The patients are with "measurable disease": serum M protein &gt;=10g/L and/or 24-hour urine M protein &gt;=200mg;
5. No active infectious diseases;
6. The main organs without serious organic disease (except for renal dysfunction, caused by the disease);
7. The patients have signed the informed consent.</inclusion_criteria>
      <agemin>18</agemin>
      <agemax>70</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. The patients have received anti-myeloma therapy (not including radiotherapy, bisphosphonate therapy, or a single short-term glucocorticoidshormone [i.e., less than or equal to prednisone 40mg / day, 5 day dose]);
2. The patients appear pain or peripheral neuropathy with two or more degree;
3. The patients have a serious thrombotic events;
4. The patients have a major surgery in 30 days;
5. The patients have other malignancy, unless the disease are in a stable situation for more than 3 years;
6. The patients are on borate, mannose, and thalidomide allergies;
7. The patients have serious infectious diseases (not cured tuberculosis, pulmonary aspergillosis);
8. The patients have epilepsy, dementia and other mental health exception demanding drug treatment;
9. There are some stats in the subjects may effect the study or study assessing (i.e., drug abuse, or other medical, psychological or social status);
10. The researchers believe that those who do not fit into this trial.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Allover response rate;Complete response rate;Safety;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Disease free survival;Progression free survival;Overall survival;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Self-financing</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2013-07-22</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>